Clinical Trials
19 trialsNCT05949632 2026-06-04
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Incyte Corporation
Phase 1/2 Terminated
NCT02834013 2026-06-03
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05947838 2026-05-18
A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal Adenocarcinoma
M.D. Anderson Cancer Center
Phase NA Recruiting
NCT07587268 2026-05-14
Molecular Profiling for Risk Stratification in Appendiceal Cancer
City of Hope Medical Center
Recruiting
NCT03074513 2026-03-11
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06207305 2026-01-13
A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05504252 2026-01-07
METIMMOX-2
University Hospital, Akershus
Phase 2 Active not recruiting
NCT06399757 2026-01-07
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Apollo Therapeutics Ltd
Phase 1/2 Recruiting
NCT00565851 2025-12-30
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03108131 2025-05-28
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05734430 2025-04-18
GAP
Vanderbilt-Ingram Cancer Center
Recruiting
NCT04665921 2025-02-07
A Study of SGN-STNV in Advanced Solid Tumors
Seagen Inc.
Phase 1 Terminated
NCT06182644 2024-01-22
FAPI
Guangdong Provincial People's Hospital
Phase NA Unknown
NCT04088786 2022-05-06
Phase I Trial HIPEC With Nal-irinotecan
Stony Brook University
Phase 1 Completed
NCT03976973 2022-03-15
BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei
Mucpharm Pty Ltd
Phase 2 Unknown
NCT03466034 2020-01-29
The Role of Hypoxia as a Selective Pressure for TP53 Mutations
Institute of Cancer Research, United Kingdom
Terminated
NCT02005965 2018-09-18
MERCURY II
Royal Marsden NHS Foundation Trust
Unknown
NCT01037049 2018-09-17
Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks
Royal Marsden NHS Foundation Trust
Phase 2 Unknown
NCT01995942 2018-09-14
MARVEL
Royal Marsden NHS Foundation Trust
Unknown